Hematology/Oncology

Top Story

Persistent mutations may predict EFS, OS outcomes in AML

August 28, 2015

Persistent leukemia-associated mutations in at least 5% of bone marrow cells in day 30 remission samples appeared to significantly increase the risk for relapse and mortality in patients with acute myeloid leukemia, according to the results of a comprehensive genomic analysis.

“Most patients with AML fall into a gray area when it comes to being able to predict their risk of relapse,” Timothy J. Ley, MD, professor of oncology and chief of the section of stem cell biology at Washington University School of Medicine in St. Louis, said in a press release. “About 80% of AML patients go into remission with chemotherapy, but most of them eventually will relapse. Unfortunately, we still don’t have a definitive test that tells us early on which patients will relapse.”

Allison W. Kurian, MD, MSc In the Journals

Impact of recurrence score assay on chemotherapy receipt varies based on breast cancer risk

August 28, 2015
The use of a 21-gene recurrence score assay appeared associated with greater use of chemotherapy in patients with low-risk breast cancer and a reduced use of…
In the Journals

Risk protocol identifies patients with cancer not allergic to carboplatin, oxaliplatin

August 28, 2015
Patients with cancer who had a history of presumed carboplatin- and oxaliplatin-induced hypersensitivity reaction did not appear allergic to the chemotherapy drugs after…
In the Journals

Intestinal obstruction a long-term risk for survivors of childhood cancer

August 28, 2015
Survivors of childhood cancer face a long-term risk for intestinal obstruction requiring surgery as a result of their treatment, according to findings from the Childhood…
Erica L. Mayer, MD, MPH In the Journals

Aromatase inhibitors improve recurrence rates, survival in early breast cancer

August 28, 2015
The use of an aromatase inhibitor reduced breast cancer recurrence rates approximately 30% compared with tamoxifen, according to the results of a meta-analysis.Further…
More News Headlines »
Tailored Therapies for Myelodysplastic Syndromes

Tailored Therapies for Myelodysplastic Syndromes

This activity is supported by an educational grant from Celgene Corporation.

Myelodysplastic syndromes (MDS) represent a group of myeloid clonal hemopathies with heterogeneous clinical…
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
CME
Hematology Oncology Case Consults

The Patient with Multiple Myeloma

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with multiple myeloma.
More »
morganatic-roan
morganatic-roan